Shots: AbCellera to receive upfront, milestone, and royalties based on the development and commercialization of Abs, emerge under the collaboration The expanded collaboration will utilize AbCellera’s technology stack, which includes […]readmore
Tags : Antibodies
In an interview with PharmaShots, Brian Finrow, Co-Founder and CEO of Lumen Bioscience shared his views on the critical need for a scalable and cheaper method to engineer antibodies as […]readmore
In an interview with PharmaShots, Tillman Gerngross, Ph.D., Co-Founder, and CEO of Adagio Therapeutics shed light on the pre-clinical data of ADG2 and how it works on SARS-CoV-2. Shots: ADG2 […]readmore
Shots: Roche has launched Elecsys Anti-SARS-CoV-2 S Ab for markets accepting the CE Mark. The company has filed for US FDA’s EUA The test can quantitatively measure the level of […]readmore
Shots: Kite enters into a two-year research collaboration and license agreement with HiFiBiO to discover novel targets and Abs against AML HiFiBiO will receive an up front and will utilize […]readmore
Shots: Singlomics to receive upfront and is eligible to receive regulatory & commercial milestones along with royalties on sales of products. BeiGene get an exclusive global right (Ex-China) to develop […]readmore
Shots: Qiagen reports the launch of the Access Anti-SARS-CoV-2 Total test that runs on a portable device and provides accurate results on Total Ig Abs (IgA, IgM, IgG) in 10mins. […]readmore
Shots: Vir will get non-exclusive access to Xencor’s Xtend Fc technology for extending the half-life of novel Abs that the company is evaluating for treating patients with COVID-19, a disease […]readmore
Shots: Biogen has signed a letter of intent with Vir to develop & manufacture mAb targeting COVID-1 and have started working together due to the urgency of the crisis while […]readmore
Shots: The companies will jointly develop, manufacture & commercialize Vir’s Ab. WuXi Biologics will conduct cell-line development, process & formulation development and initial manufacturing for clinical development Following the regulatory […]readmore